FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Lilly Q3 Results - Q3 Top Pharma Company Earnings Reports

Tools

View Lilly's Q3 Earnings Report

FiercePharma says: Lilly posted $941.8 million in third-quarter net income, way up from last year's $465.6 million loss on charges. More impressively, however, the company managed to boost sales by 6.8 percent during a quarter when its rivals had a tough time on the revenue side.. Read more of our coverage here...

Highlights:

  • Higher volume drives revenue growth
  • Stronger dollar results in improved gross margin
  • Earnings per share increase to $.86 (reported) or $1.20 (pro forma non-GAAP)
  • Full-year 2009 EPS guidance range revised to $3.90 - $4.00 (reported) or $4.30 - $4.40 (pro forma non-GAAP)

Check out Lilly's current earnings estimates from CNN Money

Lilly's Website: http://www.lilly.com/

Related Articles:
Lilly juggles jobs for emerging-markets growth
Cost-conscious Medco pits Plavix against Effient
Lilly's promo deal with CVS draws fire
Lilly offloads 700-worker Indiana plant


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Eli Lilly